Neurocrine Biosciences/ US64125C1099 /
2024-07-30 9:59:58 PM | Chg. -4.01 | Volume | Bid- | Ask- | High | Low |
---|---|---|---|---|---|---|
141.19USD | -2.76% | 85,781 Turnover: 12.16 mill. |
-Bid Size: - | -Ask Size: - | 145.42 | 139.97 |
GlobeNewswire
06-13
Voyager Therapeutics Announces Appointment of Nathan Jorgensen as Chief Financial Officer
GlobeNewswire
05-16
Voyager Therapeutics Announces First Participants Dosed in Single Ascending Dose Trial of VY-TAU01 f...
GlobeNewswire
05-09
Xenon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire
05-09
Nxera Pharma’s partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of...
GlobeNewswire
05-09
Nxera Pharma Operational Highlights and Consolidated Results for the First Quarter 2024
GlobeNewswire
05-08
Voyager Therapeutics Presents Data for Second-Generation, TRACER™-Generated Capsids and CNS Gene The...
GlobeNewswire
04-22
Voyager Therapeutics to Present Broad Set of Translational Data Supporting IV-Delivered, CNS Gene Th...
GlobeNewswire
04-16
Sentia Medical Sciences and Neurocrine Biosciences Extend Research Collaboration to Discover Novel C...
GlobeNewswire
04-16
Voyager Therapeutics Announces Selection of Development Candidate for GBA1 Program in Collaboration ...
GlobeNewswire
04-16
Nxera Pharma Notes Successful Development Progress of Partnered Schizophrenia Candidate NBI-1117568
GlobeNewswire
03-26
Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
03-13
Voyager Therapeutics Announces Appointment of Toby Ferguson as Chief Medical Officer
GlobeNewswire
02-29
Xenon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corpo...
GlobeNewswire
02-28
Voyager Therapeutics Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
GlobeNewswire
02-26
Voyager Therapeutics Announces Selection of Gene Therapy Development Candidate for Friedreich’s Atax...
GlobeNewswire
02-20
Voyager Therapeutics Reports Robust Preclinical Activity in Tau Silencing Gene Therapy Program for A...
GlobeNewswire
02-13
Sosei Heptares Operational Highlights and Consolidated Results for 12 Months ended 31 December 2023